CD137 agonism enhances anti-PD1 induced activation of expanded CD8⁺ T cell clones in a neoadjuvant pancreatic cancer clinical trial.

ABSTRACT: Successful pancreatic ductal adenocarcinoma (PDAC) immunotherapy requires therapeutic combinations that induce quality T cells. Tumor microenvironment (TME) analysis following therapeutic interventions can identify response mechanisms, informing design of effective combinations. We provide a reference single-cell dataset from tumor-infiltrating leukocytes (TILs) from a human neoadjuvant clinical trial comparing the granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting allogeneic PDAC vaccine GVAX alone, in combination with anti-PD1 or with both anti-PD1 and CD137 agonist. Treatment with GVAX and anti-PD-1 led to increased CD8⁺ T cell activation and expression of cytoskeletal and extracellular matrix (ECM)-interacting components. Addition of CD137 agonist increased

SUBMITTER: Montagne JM 

PROVIDER: S-EPMC11730579 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature